Saprochaete capitata as an emerging fungus among patients with haematological malignencies

Ulu-Kilic A., ATALAY M. A., Metan G., Cevahir F., Koc N., Eser B., ...More

MYCOSES, vol.58, no.8, pp.491-497, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 58 Issue: 8
  • Publication Date: 2015
  • Doi Number: 10.1111/myc.12347
  • Journal Name: MYCOSES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.491-497
  • Hacettepe University Affiliated: Yes


Saprochaete capitata is a very rare pathogen that causes invasive disease particularly in patients with haematological malignancies. We recognised a clustering of S.capitata fungaemia in recent years. So, we report our 6-year surveillance study of fungaemia among patients with haematological malignancies and haematopoietic stem cell transplant. We performed a retrospective and observational study. Hospitalised patients aged >18years with haematological malignancies were included in the study. A total of 51 fungaemia episodes of 47 patients were analysed. The characteristics of fungaemia in patients with S.capitata compared to patients with candidemia. Median duration of neutropenia was 21.5 days in patients with S.capitata fungaemia, whereas this duration was significantly shorter in patients with candidemia (8days). Interval between first and last positive culture was significantly longer in patients with S.capitata fungaemia (P<0.05). Previous use of caspofungin was significantly more common in patients with S.capitata fungaemia. Thirty-day mortality was found 40% for patients with candidemia, whereas it was 39% for patients with S.capitata. In conclusion, despite its limitations this study showed that a novel and more resistant yeast-like pathogen become prevalent due to use of caspofungin in patients with long-lasting neutropenia which was the most noteworthy finding of this 6-year surveillance study.